How Seaport is hedging against failure in Phase 2b depression studynews2026-03-25T18:00:28+00:00March 25th, 2026|Endpoints News|
FDA approves Corcept’s Lifyorli for ovarian cancer months earlynews2026-03-25T17:12:25+00:00March 25th, 2026|Endpoints News|
After tumultuous year, Sarepta plots rebound with early data on RNA therapiesnews2026-03-25T15:41:06+00:00March 25th, 2026|Endpoints News|
Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressurenews2026-03-25T15:14:06+00:00March 25th, 2026|Endpoints News|
Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblixnews2026-03-25T10:47:34+00:00March 25th, 2026|Endpoints News|
Biotech investors set to meet with key congressional panelnews2026-03-24T12:00:02+00:00March 24th, 2026|Endpoints News|
Apnimed set to exit sleep disorder joint venture with Shionogi for $100M upfrontnews2026-03-24T11:19:25+00:00March 24th, 2026|Endpoints News|
Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch innews2026-03-24T10:41:57+00:00March 24th, 2026|Endpoints News|
WuXi AppTec’s bet on the US pays off as revenues dip elsewherenews2026-03-23T15:24:18+00:00March 23rd, 2026|Endpoints News|
Arikayce could become Insmed’s second blockbuster following late-stage win in lung infectionnews2026-03-23T11:01:00+00:00March 23rd, 2026|Endpoints News|
